Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | PAM | P19021 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CHAT | P28329 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL692304 | 0.77 | CA1 (0.52) | HTR2AIDO1PAMMAOBCA1 | |
| SCHEMBL692303 | 0.77 | CA1 (0.52) | HTR2AIDO1PAMMAOBCA1 | |
| SCHEMBL4863423 | 0.75 | IDO1 (0.58) | HTR2AIDO1PAMMAOBRELA | |
| SCHEMBL9777486 | 0.75 | IDO1 (0.58) | HTR2AIDO1PAMMAOBRELA | |
| SCHEMBL4528665 | 0.73 | HTR2A (0.54) | HTR2AIDO1PAMMAOBSIGMAR1 | |
| SCHEMBL178030 | 0.73 | HTR2A (0.54) | HTR2AIDO1PAMMAOBSIGMAR1 | |
| SCHEMBL455862 | 0.73 | HTR2A (0.54) | HTR2AIDO1PAMMAOBSIGMAR1 | |
| SCHEMBL14961 | 0.73 | HTR2A (0.54) | HTR2AIDO1PAMMAOBSIGMAR1 | |
| SCHEMBL1961951 | 0.73 | IDO1 (0.52) | HTR2AIDO1PAMMAOBSIGMAR1 | |
| Benzene SCHEMBL1226473 | 0.73 | HTR2A (0.54) | HTR2AIDO1PAMMAOBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193394-B2 | Process for production of lasofoxifene or analogue thereof | TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20090012314-A1 | Process for Production of Lasofoxifene or Analogue Thereof | TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1982981-A1 | PROCESS FOR PRODUCTION OF LASOFOXIFENE OR ANALOGUE THEREOF | Tokyo University of Science, Educational Foundation (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-1960411-A1 | HALOGEN SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | ExxonMobil Chemical Patents Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007070040-A1 | HALOGEN SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012314-A1 | Process for Production of Lasofoxifene or Analogue Thereof | CYP19A1, CYP2F1, HSD17B11 | HTR2A 3236/4885IDO1 3487/4885PAM 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.